The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 26, 2022
Filed:
Apr. 18, 2019
Applicant:
Cedars-sinai Medical Center, Los Angeles, CA (US);
Inventors:
Kathrin S. Michelsen, Los Angeles, CA (US);
Stephan R. Targan, Santa Monica, CA (US);
Assignee:
CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C12Q 1/68 (2018.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/564 (2006.01); G01N 33/96 (2006.01); G01N 33/68 (2006.01); C07K 16/24 (2006.01); A61K 45/06 (2006.01); C12Q 1/6883 (2018.01); G01N 33/483 (2006.01); C07K 14/54 (2006.01); C07K 14/525 (2006.01); G01N 33/569 (2006.01); G01N 15/14 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/241 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/244 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6883 (2013.01); G01N 33/483 (2013.01); G01N 33/50 (2013.01); G01N 33/53 (2013.01); G01N 33/68 (2013.01); G01N 33/6863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 33/56966 (2013.01); G01N 2015/149 (2013.01); G01N 2333/5425 (2013.01); G01N 2333/70575 (2013.01); G01N 2800/065 (2013.01); G01N 2800/12 (2013.01); G01N 2800/24 (2013.01); G01N 2800/7095 (2013.01);
Abstract
The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TL17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.